Results
The study included 7,176 ABR
tests (6,106 patients) between December 2015 and March 2022. A total of
3101(43.21%) ABR tests were females and 4075(56.79%) ABR tests were
males. The median (interquartile range [IQR]) age was 1(8 – 0.42)
year, with a range of 1 month to 84 years. There were 223(3.11%) ABR
tests which were sedation failed. A total of 102(45.74%) ABR tests were
females and 121(54.26%) ABR tests were males. The median (interquartile
range [IQR]) age was 1(3 – 0.42) year, with a range of 1 month to
68 years. When we grouped patients by age (≤0.5 years, 0.5-3 years, 3-12
years, ≥12 years), the failure rates ranged from 1.44% to 4.31%, with
significant differences (P <0 .001) (Table 1)(Table
2).
Some infants and children need to mix the medicine with dairy products
or other liquids, to facilitate better medication. There were
99(44.40%) ABR tests in the mixed group and 124(55.60%) ABR tests in
the direct group. According to telephone follow-up results, the sedation
performance was divided into three categories, of which 166(74.44%) ABR
tests were insufficient sedation after taking Chloral Hydrate. Fifty
(22.42%) ABR tests were unable to fall asleep and 7(3.14%) ABR tests
were in superficial sleep. The vast majority of patients reported
performing sleep deprivation, but the specific implementation has not
been followed up. Most patients (43.05%) in the mixed group were
younger than 3 years old, and patients over 3 years old were mainly
taken Chloral Hydrate directly, there were significant differences
between the administration method among different age groups (P< 0.001). Insufficient sedation was the main performance of
sedation failure in the ≤0.5 years group and the 0.5-3 years group.
Failure to sleep was the main performance of sedation failure in the ≥12
years group. In addition, there were 6(2.69%) ABR tests in the≥12 years
group and only 1(0.45%) ABR tests in the group of ≤0.5 years who were
in superficial sleep. There were significant differences in the failure
performance among different age groups (P < 0.001)
(Table 2).
No severe adverse event (apnea, bradycardia) was observed in our study.
The adverse events included 25(0.35%) ABR tests that experienced minor
adverse events such as vomiting, agitation, and tension. There were
18(0.25%) ABR tests experienced vomiting, and 5(0.07%) ABR tests
experienced agitation, and 2(0.03%) ABR tests experienced tension
throughout the test (Table 1).